BDRX

Biodexa Pharmaceuticals plc Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website biodexapharma.com
Employees(FY) 27
ISIN US59564R8079

Performance

+1.29%

+8.79%

-28.93%

-74.16%

+8.79%

YTD

-89.05%

Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of BDRX 2025-01-31

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 56 indicating a slight bullish bias, while the Oscillators Score remains neutral at 50, and the Technical Score also at 55 suggests a cautious outlook. This combination implies that while there is some upward momentum, the market lacks strong conviction, w...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BDRX

Stock Rank

Recent News & Updates

2024-05-08 20:00
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition(Accesswire)
2024-04-29 23:52
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting(Globenewswire)
2024-04-28 00:01
12 ChatGPT Penny Stock Picks Right Now(Insidermonkey)
2024-04-26 03:18
Why Is Biodexa (BDRX) Up 70% Today?(Investorplace)
2024-04-25 20:30
Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)(Globenewswire)
2024-04-18 20:00
Preliminary Results for the Year Ended 31 December 2023(Globenewswire)
2024-03-27 23:22
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?(Investorplace)
2024-03-27 20:15
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers(Accesswire)
2024-02-29 19:00
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone(Accesswire)
2024-02-22 19:30
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update(Globenewswire)
2024-02-07 19:30
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients(Globenewswire)
2024-02-06 19:30
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone(Globenewswire)
2024-01-21 19:30
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024(Globenewswire)
2023-12-28 15:05
Biodexa Appoints Ann Merchant to the Board of Directors(Globenewswire)
2023-12-21 03:00
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option(Globenewswire)
2023-12-18 19:42
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering(Globenewswire)
2023-11-26 20:00
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes(Globenewswire)
2023-10-02 20:30
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma(Globenewswire)
2023-09-29 04:30
Interim results for the six months ended 30 June 2023(Globenewswire)
2023-09-20 20:30
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)(Yahoo Finance)
2023-07-27 20:00
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites(Yahoo Finance)
2023-07-23 19:30
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement(Yahoo Finance)
2023-07-09 20:00
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)(Yahoo Finance)
2023-07-06 04:30
Results of Appeal of Delisting Determination(Yahoo Finance)
2023-07-05 20:15
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)(Yahoo Finance)
2023-06-22 04:15
ADR Ratio Change(Yahoo Finance)
2023-06-19 20:00
Appeal of Delisting Determination(Yahoo Finance)
2023-06-15 04:05
Receipt of NASDAQ Delisting Determination Plans to Appeal(Yahoo Finance)
2023-06-13 20:30
Results of Annual General Meeting and General Meeting(Yahoo Finance)
2023-05-26 04:05
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering(Yahoo Finance)

Page 2 of 3

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.